Morpholin-2-ylmethanol → [4-(4-{5-[1-(2-fluorophenyl)-5-pyridin-4-yl-1H-1,2,3-triazol-4-yl]-1,2,4-oxadiazol-3-yl}benzyl)morpholin-2-yl]methanol

참여 물질

반응 단계

The title compound was prepared following the procedure described for Example 94, but starting from 4-(5-(1-(2-fluorophenyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)-1,2,4-oxadiazol-3-yl)benzaldehyde, obtained as described in Example 113, Step 1, (100 mg; 0.24 mmol) and morpholin-2-ylmethanol (56.8 mg; 0.48 mmol) to give Example 143 as a white solid. 1H NMR: (DMSO-d6, 400 MHz) δ 8.75 (2H, dd, J=4.7, 1.6 Hz), 7.97 (2H, d, J=7.9 Hz), 7.94-7.87 (1H, m), 7.76-7.69 (1H, m), 7.61 (2H, dd, J=4.7, 1.6 Hz), 7.58-7.48 (4H, m), 4.65 (1H, t, J=5.6 Hz), 3.80 (1H, d, J=11.2 Hz), 3.62-3.50 (3H, m), 3.46-3.39 (2H, m), 3.34-3.28 (1H, m), 2.79 (1H, d, J=11.1 Hz), 2.66 (1H, d, J=11.4 Hz), 2.12 (1H, td, J=11.3, 3.3 Hz), 1.84 (1H, t, J=10.4 Hz). LC/MS (Method C): 514 (M+H)+. HPLC (Method E) Rt 2.12 min (Purity: 99.9%).

출처 및 근거